Recent News

• 03.11.2026 - BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
• 03.10.2026 - BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
• 03.05.2026 - BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
• 02.19.2026 - BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
• 02.12.2026 - BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
• 01.20.2026 - BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
• 01.12.2026 - BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

Recent Filings

• 03.11.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.11.2026 - 8-K Current report
• 02.12.2026 - 8-K Current report
• 02.09.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.06.2026 - 8-K Current report
• 01.20.2026 - 8-K Current report
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities